1-3 of 3
Carolyn M. Cheney
Close
Sort by
Journal Articles

GlycoVariant Anti-CD37 Small Modular Immuno-Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density

Sarwish Rafiq, MA, Carolyn M Cheney, BS, Gerard Lozanski, MD, Rosa Lapalombella, PhD, Xiaokui Mo, PhD, Anthony Siadak, MD, David Jarjoura, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD
Journal: Blood
Blood (2010) 116 (21): 1847.
https://doi.org/10.1182/blood.V116.21.1847.1847
Published: 2010
Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Jennifer Swenor, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Carolyn M. Cheney, MS, David M. Lucas, PhD, Donn Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD
Journal: Blood
Blood (2004) 104 (11): 3469.
https://doi.org/10.1182/blood.V104.11.3469.3469
Published: 2004
Journal Articles

Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells

Andrew P. Mone, Peng Huang, Helene Pelicano, Carolyn M. Cheney, Jennifer M. Green, J. Yun Tso, Amy J. Johnson, Sara Jefferson, Thomas S. Lin, John C. Byrd
Journal: Blood
Blood (2004) 103 (5): 1846–1854.
https://doi.org/10.1182/blood-2003-08-2836
Published: 2004